Researchers have developed an intelligent monitoring and evaluation system for adverse drug reactions

The reporter learned from the Third Xiangya Hospital of Central South University on July 20 that the team of Yang Guoping, a professor at the Clinical Trial Research Center of the hospital, recently published important research results on intelligent monitoring of adverse drug reactions in the “Briefings in Bioinformatics”. Yang Guoping and Professor Cao Dongsheng of Central South University are the co-corresponding authors of the paper, doctoral students Feng Zeying and Wu Xuehong of Central South University are the co-first authors of the paper, and the Third Xiangya Hospital of Central South University is the first and corresponding author unit.

Adverse drug reactions (ADRs) are a serious threat to drug safety and have become a global public health problem. Timely monitoring and detection of ADRs occurring during hospitalization is important to compensate for the limitations of premarket studies and reduce the recurrence of ADRs.

Thanks to the development of artificial intelligence technology, natural language processing (NLP) technology can realize the intelligent recognition of ADR events in medical texts, but NLP research in Chinese started late, lacked open relevant corpus and training resources, and it was quite challenging to identify ADR events from Chinese electronic medical record text.

In view of the above problems, Professor Yang Guoping’s team organized a large number of clinical corpus annotations, and built an ADR event intelligent recognition system based on deep learning and knowledge graph technology, which has been externally verified to have a robust recognition effect, providing a powerful tool for drug safety research and automated drug adverse event monitoring.

In this study, drug knowledge graph technology was innovatively introduced to reason about completing the missing drug descriptions in ADR events and screening and identifying new ADRs, and the related technical solutions have been authorized by national patents (patent number: ZL 2022 1 0102746.8). At the same time, the research team has developed the Intelligent Monitoring and Evaluation System for Adverse Drug Reactions (AIMES) based on the core technology of the system, and the AIMES system has been deployed for clinical trials.

Overview of ADR event intelligent recognition system. Photo courtesy of interviewee

According to reports, in recent years, Professor Yang Guoping’s team has successively developed the world’s first “gene face” system, the first domestic clinical pharmacology modeling and statistical cloud platform, an adverse drug reaction intelligent monitoring and evaluation system, and a clinical research electronic record and information interaction system through multidisciplinary cross-cooperation. (Source: China Science News, Wang Haohao, Xiang Yuxia)

Related paper information:

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button